Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY26 results · Oct–Dec 2025
Glenmark Pharmaceuticals reported revenue from operations of ₹3,900.61 crore (up 15.1% from Q3 FY25) and net profit of ₹403.23 crore (up 15.9% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,900.61 | 3,387.55 | +15.1% | 6,046.87 | −35.5% |
| Other income | 44.47 | 31.13 | +42.8% | 200.63 | −77.8% |
| Total income | 3,945.08 | 3,418.68 | +15.4% | 6,247.50 | −36.9% |
| Profit before tax | 534.00 | 456.33 | +17.0% | 967.40 | −44.8% |
| Net profit for the period | 403.23 | 348.03 | +15.9% | 610.43 | −33.9% |
| Attributable to shareholders of the company | 403.21 | — | — | 610.35 | −33.9% |
| EPS, basic (₹) | 14.29 | 12.33 | +15.9% | 21.63 | −33.9% |
| Net margin (%) | 10.3 | 10.3 | 10.1 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,359.93 | 2,251.28 | +4.8% | 1,538.66 | +53.4% |
| Other income | 109.06 | 129.19 | −15.6% | 285.76 | −61.8% |
| Total income | 2,468.99 | 2,380.47 | +3.7% | 1,824.42 | +35.3% |
| Profit before tax | 346.53 | 559.49 | −38.1% | (906.37) | Turned profit |
| Net profit for the period | 282.07 | 413.80 | −31.8% | (739.19) | Turned profit |
| EPS, basic (₹) | 10.00 | 14.66 | −31.8% | (26.19) | Turned profit |
| Net margin (%) | 12.0 | 18.4 | -48.0 |
Consolidated
- Filed with BSE
- 30 Jan 2026, 20:22 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2026, 20:22 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE